$NKTR
NEKTAR THERAPEUTICS Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000090670921000018 Filed on November 05, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$25.01M	$24.92M	$30.03M
YoY Change	6.59%	-17.02%	2.79%
Cost Of Revenue	$6.163M	$5.311M	$5.570M
YoY Change	42.56%	-4.65%	13.05%
Gross Profit	$18.85M	$19.61M	$24.46M
YoY Change	-1.53%	-19.84%	0.71%
Gross Profit Margin	75.36%	78.69%	81.45%
Selling, General & Admin	$32.14M	$29.47M	$27.00M
YoY Change	18.61%	9.14%	12.5%
% of Gross Profit	170.55%	150.27%	110.37%
Research & Development	$99.61M	$103.7M	$100.5M
YoY Change	-3.03%	3.19%	1.5%
% of Gross Profit	528.57%	529.01%	410.95%
Depreciation & Amortization	$3.436M	$3.620M	$3.200M
YoY Change	4.12%	13.13%	-8.57%
% of Gross Profit	18.23%	18.46%	13.08%
Operating Expenses	$99.61M	$103.7M	$100.5M
YoY Change	-3.03%	3.19%	1.5%
Operating Profit	-$112.9M	-$113.6M	-$103.1M
YoY Change	1.98%	10.23%	4.36%
Interest Expense	-$8.329M	$0.00	$0.00
YoY Change	30.14%		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$24.41M	-$16.00M	-$5.515M
YoY Change		190.08%	-2271.26%
Pretax Income	-$145.6M	-$129.6M	-$108.6M
YoY Change	24.38%	19.37%	10.23%
Income Tax	-$4.000K	$112.0K	$21.00K
% Of Pretax Income
Net Earnings	-$145.6M	-$129.7M	-$108.6M
YoY Change	24.27%	19.45%	10.14%
Net Earnings / Revenue	-582.37%	-520.47%	-361.56%
Basic Earnings Per Share	-$790.00	-$700.00	-$0.61
Diluted Earnings Per Share	-$790.00	-$700.00	-$0.61
COMMON SHARES
Basic Shares Outstanding	184.6M shares	184.1M shares	179.1M shares
Diluted Shares Outstanding		184.1M shares	179.1M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$734.0M	$921.1M	$956.0M
YoY Change	-30.88%	-3.65%	-36.08%
Cash & Equivalents	$25.22M	$54.02M	$55.84M
Short-Term Investments	$708.7M	$867.1M	$900.2M
Other Short-Term Assets	$23.33M	$20.73M	$21.55M
YoY Change	6.41%	-3.8%	41.66%
Inventory	$15.80M	$15.33M	$12.89M
Prepaid Expenses
Receivables	$22.49M	$28.99M	$42.93M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$795.6M	$986.1M	$1.044B
YoY Change	-30.09%	-5.53%	-33.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$60.51M	$58.83M	$60.19M
YoY Change	1.42%	-2.26%	-6.85%
Goodwill	$76.50M	$76.50M	$76.50M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$64.83M	$34.22M	$197.7M
YoY Change	-52.58%	-82.69%	-14.45%
Other Assets	$2.744M	$1.844M	$1.420M
YoY Change	87.82%	29.86%	-40.46%
Total Long-Term Assets	$321.6M	$291.1M	$464.8M
YoY Change	-19.75%	-37.37%	-8.77%
TOTAL ASSETS
Total Short-Term Assets	$795.6M	$986.1M	$1.044B
Total Long-Term Assets	$321.6M	$291.1M	$464.8M
Total Assets	$1.117B	$1.277B	$1.509B
YoY Change	-27.4%	-15.34%	-27.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.747M	$23.66M	$15.48M
YoY Change	-55.97%	52.8%	-29.5%
Accrued Expenses	$75.45M	$116.3M	$110.5M
YoY Change	-19.3%	5.26%	16.32%
Deferred Revenue			$507.0K
YoY Change			-93.96%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$85.20M	$140.0M	$126.5M
YoY Change	-26.41%	10.65%	0.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$3.592M	$3.869M	$3.291M
YoY Change	-60.0%	17.56%	411.82%
Total Long-Term Liabilities	$3.592M	$3.869M	$3.291M
YoY Change	-60.0%	17.56%	411.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$85.20M	$140.0M	$126.5M
Total Long-Term Liabilities	$3.592M	$3.869M	$3.291M
Total Liabilities	$437.7M	$475.7M	$337.7M
YoY Change	-5.16%	40.87%	-43.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.833B	-$2.687B	-$2.192B
YoY Change	22.69%	22.6%	25.16%
Common Stock	$3.517B	$3.492B	$3.364B
YoY Change	3.77%	3.82%	3.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$679.5M	$801.5M	$1.171B
YoY Change
Total Liabilities & Shareholders Equity	$1.117B	$1.277B	$1.509B
YoY Change	-27.4%	-15.34%	-27.76%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$145.6M	-$129.7M	-$108.6M
YoY Change	24.27%	19.45%	10.14%
Depreciation, Depletion And Amortization	$3.436M	$3.620M	$3.200M
YoY Change	4.12%	13.13%	-8.57%
Cash From Operating Activities	-$151.5M	-$101.1M	-$52.70M
YoY Change	53.69%	91.91%	-23.29%
INVESTING ACTIVITIES
Capital Expenditures	-$5.896M	-$2.936M	-$1.900M
YoY Change	227.56%	54.53%	-64.15%
Acquisitions
YoY Change
Other Investing Activities	$126.1M	$2.106M	$50.60M
YoY Change	33.43%	-95.84%	-20.44%
Cash From Investing Activities	$120.2M	-$830.0K	$48.70M
YoY Change	29.66%	-101.7%	-16.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.552M	3.663M	1.600M
YoY Change	-98.29%	128.94%	-74.19%
NET CHANGE
Cash From Operating Activities	-151.5M	-101.1M	-52.70M
Cash From Investing Activities	120.2M	-830.0K	48.70M
Cash From Financing Activities	2.552M	3.663M	1.600M
Net Change In Cash	-28.79M	-98.30M	-2.400M
YoY Change	-120.13%	3995.96%	-44.19%
FREE CASH FLOW
Cash From Operating Activities	-$151.5M	-$101.1M	-$52.70M
Capital Expenditures	-$5.896M	-$2.936M	-$1.900M
Free Cash Flow	-$145.6M	-$98.20M	-$50.80M
YoY Change	50.46%	93.31%	-19.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-24006
	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
	dei	City Area Code CityAreaCode	415
	dei	Local Phone Number LocalPhoneNumber	482-5300
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	NKTR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	184557124	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54017000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198955000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	867063000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	862941000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28994000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	38889000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	15330000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	15292000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	20731000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	21928000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	986135000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1138005000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	34219000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	136662000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58830000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59662000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	119714000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	126476000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	76501000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1844000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1461000	USD
CY2021Q3	us-gaap	Assets Assets	1277243000	USD
CY2020Q4	us-gaap	Assets Assets	1538767000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	23660000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22139000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	32882000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14532000	USD
CY2021Q3	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	37633000	USD
CY2020Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	44207000	USD
CY2021Q3	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	8088000	USD
CY2020Q4	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	11310000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19966000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9676000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17740000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13915000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	139969000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	115779000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	128718000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136373000	USD
CY2021Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	21387000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2021Q3	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	181760000	USD
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	200340000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3869000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8980000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	475703000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	461472000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184554000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	180091000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3492435000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3388730000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3563000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2295000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2687350000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2309158000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	801540000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1277243000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1538767000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24921000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30033000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76898000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	129453000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5311000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5570000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18734000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15154000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103738000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100531000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	300655000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	305954000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29468000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26982000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	90702000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	77546000	USD
CY2021Q3	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	0	USD
CY2020Q3	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	0	USD
	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	0	USD
	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	45189000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	138517000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	133083000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	410091000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	443843000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-113596000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-103050000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-333193000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-314390000	USD
CY2021Q3	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	12801000	USD
CY2020Q3	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	8425000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	39186000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	22084000	USD
CY2021Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3328000	USD
CY2020Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-7640000	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	131000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2910000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2388000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16453000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	6851000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15998000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5515000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-44438000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12482000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-129594000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-108565000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-377631000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-326872000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	561000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	365000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-129706000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-108586000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-378192000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-327237000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.84
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.84
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	184110000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	184110000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179090000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179090000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	182736000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	182736000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	178203000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	178203000	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-129706000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-108586000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-378192000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-327237000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-176000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2144000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1006000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	423000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	13000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	349000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-262000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-498000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-163000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1795000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1268000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-75000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-129869000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110381000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-379460000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-327312000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11347000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24211000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144523000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1296426000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7826000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24396000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72408000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1256240000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1455000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23667000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110381000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1170981000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	17106000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23898000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-123793000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	994506000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12553000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23714000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-125798000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	904975000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1777000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24657000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-129869000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	801540000	USD
	us-gaap	Profit Loss ProfitLoss	-378192000	USD
	us-gaap	Profit Loss ProfitLoss	-327237000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	58667000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	28001000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	39186000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	22084000	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-7640000	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	11497000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72269000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72274000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10710000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10937000	USD
	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	USD
	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	20351000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5677000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1150000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9895000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6123000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	38000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	227000	USD
	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2932000	USD
	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-4316000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-814000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5588000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1247000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3337000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	18350000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	20478000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3837000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	9340000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-605000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5070000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-261122000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-214653000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	816049000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	791445000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	902687000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1158722000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5035000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9093000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5504000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	82580000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	403473000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	31436000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	20651000	USD
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	2250000	USD
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	250000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33686000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-229349000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-82000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-144938000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40520000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54017000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55843000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	9742000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1057000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2133000	USD
CY2021Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	955300000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of September 30, 2021, our accounts receivable includes $24.9 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $3.1 million under customer contracts from our collaboration partners. As of December 31, 2020, our accounts receivable included $38.7 million for unbilled net expense reimbursements from BMS and $0.2 million from customer contracts. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three and nine months ended September 30, 2021 and 2020. We have not recorded a reserve for credit losses at September 30, 2021 or December 31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a deterioration in this industry could have a material effect on our results of operations and financial position. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors, including the effects of the COVID-19 pandemic, result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div>
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q3	nktr	Sale Of Stock Value Authorized In Transaction SaleOfStockValueAuthorizedInTransaction	300000000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54017000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198955000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	867063000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	862941000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	34219000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	136662000	USD
CY2021Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	955299000	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1198558000	USD
	nktr	Debt Investment Maximum Maturity Period DebtInvestmentMaximumMaturityPeriod	P2Y
	nktr	Debt Investment Maturity Term DebtInvestmentMaturityTerm	P1Y
CY2021Q3	us-gaap	Cash Cash	5681000	USD
CY2020Q4	us-gaap	Cash Cash	6285000	USD
CY2021Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	955299000	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1198558000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1100000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	200000	USD
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1744000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2422000	USD
CY2021Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9388000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10703000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4198000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2167000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	15330000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	15292000	USD
CY2021Q3	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	314000	USD
CY2020Q3	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	1631000	USD
	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	396000	USD
	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	55421000	USD
CY2021Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	19400000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	58700000	USD
CY2020Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	22700000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	109400000	USD
CY2021Q3	nktr	Potential Development And Regulatory Milestones PotentialDevelopmentAndRegulatoryMilestones	1700000000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24657000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23667000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72269000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72274000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	397000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	233000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	674000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	282000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.36
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.68
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17634000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16575000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18454000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17499000	shares

Files In Submission

Name	View Source	Status
0000906709-21-000018-index-headers.html	Edgar Link	pending
0000906709-21-000018-index.html	Edgar Link	pending
0000906709-21-000018.txt	Edgar Link	pending
0000906709-21-000018-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20210930.htm	Edgar Link	pending
nktr-20210930.xsd	Edgar Link	pending
nktr-20210930_cal.xml	Edgar Link	unprocessable
nktr-20210930_def.xml	Edgar Link	unprocessable
nktr-20210930_htm.xml	Edgar Link	completed
nktr-20210930_lab.xml	Edgar Link	unprocessable
nktr-20210930_pre.xml	Edgar Link	unprocessable
nktr2021-09x30xexx311.htm	Edgar Link	pending
nktr2021-09x30xexx312.htm	Edgar Link	pending
nktr2021-09x30xexx321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
NEKTAR THERAPEUTICS Stock $nktr

2021 Q4 Form 10-Q Financial Statement

#000090670921000018 Filed on November 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR NEKTAR THERAPEUTICS Stock $nktr

2021 Q4 Form 10-Q Financial Statement

#000090670921000018 Filed on November 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
NEKTAR THERAPEUTICS Stock $nktr